文献速递妇科产科

综合二代测序在同时性输卵管卵巢与子宫内膜浆液性及子宫内膜样癌或前驱病变患者中识别新的推测致病性或可能致病性胚系变异

Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors.
PubMed 文献 · Gynecol Oncol · 2024-06-03

本研究对5例同时性子宫内膜浆液性癌、输卵管卵巢高级别浆液性癌或前驱病变合并子宫内膜不典型增生或低级别子宫内膜样腺癌患者,用包含523个基因的TSO 500 panel对肿瘤及配对良性组织进行靶向二代测序,在4/5例中发现癌症易感基因的胚系致病性、可能致病性或意义不明变异,涉及GLI1、PIK3R1、FOXP1、FANCD2、INPP4B和H3F3C,这些基因均不在最初用于评估患者的商业化胚系检测panel中。作者认为对这类患者进行综合胚系检测可能有助于早期识别有患癌风险的亲属,这些亲属可能是行降低风险输卵管卵巢切除术加子宫切除术的候选者。

要点

  • 5例同时性ESC、HGSC或前驱病变合并CAH或LGEEA患者中,4例检出癌症易感基因胚系变异。
  • 检出的GLI1、PIK3R1、FOXP1、FANCD2、INPP4B和H3F3C均不在最初使用的商业化胚系检测panel中。
  • 作者认为综合胚系检测可能有助于早期识别有患癌风险的亲属,这些亲属可能是行RRSO加子宫切除术的候选者。

核心结论

  • 对同时性LGEEA或CAH合并ESC、HGSC或前驱病变的患者进行综合胚系检测,可能有助于早期识别有患癌风险的亲属,这些亲属可能是行降低风险输卵管卵巢切除术加子宫切除术的候选者。

研究设计与样本

  • 采用包含523个基因的TSO 500 panel,对5例同时性ESC、HGSC或前驱病变合并CAH或LGEEA患者的福尔马林固定石蜡包埋肿瘤及配对良性非肿瘤组织块进行靶向二代测序。

主要发现

  • 5例患者中4例检出癌症易感基因的胚系致病性、可能致病性或意义不明变异,涉及基因包括GLI1、PIK3R1、FOXP1、FANCD2、INPP4B和H3F3C。
  • 这些基因均不在患者确诊时最初用于评估的商业化胚系检测panel中。

临床怎么用

  • 作者认为对同时性LGEEA或CAH合并ESC、HGSC或前驱病变的患者进行综合胚系检测可能有助于早期识别有患癌风险的亲属,这些亲属可能是行RRSO加子宫切除术的候选者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endometrial serous carcinoma (ESC) and tubo-ovarian high-grade serous carcinoma (HGSC) are characterized by late-stage presentation and high mortality. Current guidelines for prevention recommend risk-reducing salpingo-oophorectomy (RRSO) in patients with hereditary mutations in cancer susceptibility genes. However, HGSC displays extensive genetic heterogeneity with alterations in 168 genes identified in TCGA study, but current germline testing panels are often limited to the handful of recurrently mutated genes, leaving families with rare hereditary gene mutations potentially at-risk. OBJECTIVE: To determine if there are rare germline mutations that may aid in early identification of more patients at-risk for ESC and/or HGSC by evaluating patients with concurrent ESC, HGSC or precursor lesions, and endometrial atypical hyperplasia (CAH) or low-grade endometrial endometrioid adenocarcinoma (LGEEA). METHODS: We performed targeted next-generation sequencing using TSO 500, a 523 gene panel, on formalin-fixed paraffin-embedded tumor and matched benign non-tumor tissue blocks from 5 patients with concurrent ESC, HGSC or precursor lesions, and CAH or LGEEA. RESULTS: We identified germline pathogenic, likely pathogenic or uncertain significance variants in cancer susceptibility genes in 4 of 5 patients - affected genes included GLI1, PIK3R1, FOXP1, FANCD2, INPP4B and H3F3C. Notably, none of these genes were included in the commercially available germline testing panels initially used to evaluate the patients at the time of their diagnoses. CONCLUSION: Comprehensive germline testing of patients with concurrent LGEEA or CAH and ESC, HGSC or precursor lesions may aid in early identification of relatives at-risk for cancer who may be candidates for RRSO with hysterectomy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Aisagbonhi O, Ghlichloo I, Hong DS, et al. Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors. Gynecol Oncol. 2024. PMID: 38833993. doi:10.1016/j.ygyno.2024.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。